尿CXCL-9在免疫检查点抑制剂相关急性间质性肾炎无创诊断中优于TNF-α
本研究前瞻性纳入免疫检查点抑制剂(ICI)治疗后发生急性肾损伤(AKI)的患者,比较尿CXCL-9与TNF-α对ICI相关急性间质性肾炎(ICI-AIN)的诊断价值,并在西班牙活检确诊队列中外部验证。结果显示尿CXCL-9区分ICI-AIN与ICI-Non-AIN AKI的AUC为0.83,显著优于TNF-α的0.63。
要点
- 尿CXCL-9诊断ICI-AIN的AUC为0.83,优于尿TNF-α的0.63。
- 尿CXCL-9在ICI-AIN患者中显著高于ICI-Non-AIN AKI及无AKI患者。
- 即使既往使用过糖皮质激素,尿CXCL-9仍具诊断优势。
核心结论
- 尿CXCL-9作为无创诊断ICI-AIN的生物标志物优于尿TNF-α,即使既往使用过糖皮质激素仍具优势。
研究设计与样本
- 前瞻性纳入Mayo队列接受ICI治疗并发生AKI的患者(ICI-AIN n=40,ICI-Non-AIN AKI n=36)及无AKI患者(n=16),用ELISA检测尿CXCL-9和TNF-α。
- 在西班牙活检确诊ICI-AIN队列(n=19)中进行外部验证。
主要发现
- Mayo队列中ICI-AIN患者尿CXCL-9水平显著高于ICI-Non-AIN AKI和无AKI患者(均P≤.0001)。
- 西班牙验证队列中ICI-AIN患者尿CXCL-9水平显著高于对照(P=.0008和<.0001)。
- 尿CXCL-9区分活检确诊ICI-AIN(两队列合并n=45)与ICI-Non-AIN AKI的AUC为0.83(95%CI 0.74-0.92),尿TNF-α的AUC为0.63(95%CI 0.51-0.75)。
关键数值与推荐
- 尿CXCL-9诊断ICI-AIN的AUC为0.83(95%CI 0.74-0.92)。
- 尿TNF-α诊断ICI-AIN的AUC为0.63(95%CI 0.51-0.75)。
临床怎么用
- 对于ICI治疗后发生AKI的患者,检测尿CXCL-9有助于无创鉴别ICI-AIN与其他原因AKI,减少肾活检需求。
局限性
- 外部验证队列样本量较小(n=19),仍需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although kidney biopsy remains the gold standard for diagnosing immune checkpoint inhibitors-associated acute interstitial nephritis (ICI-AIN), several promising urinary biomarkers have emerged as potential non-invasive diagnostics. Notably, recent studies have highlighted tumor necrosis factor alpha (TNF-α), CXC motif chemokine ligand 9 (CXCL-9) and others as potential biomarkers to help distinguish ICI-AIN from other causes of acute kidney injury (AKI). However, a direct systematic comparison between these two biomarkers in a cohort of patients undergoing immunotherapy has not been performed. METHODS: We prospectively enrolled a cohort of ICI-treated cancer patients who developed AKI (including both ICI-AIN and ICI-Non-AIN AKI), as well as those without AKI, referred to as the internal validation cohort. Urinary CXCL-9 and TNF-α were measured across all groups using the human Quantikine ELISA Kit. We externally validated our findings in a cohort of biopsy proven ICI-AIN patients from Spain, referred to as the external validation cohort. RESULTS: Urinary CXCL-9 levels were significantly higher in ICI-AIN patients from Mayo (n = 40) compared with those with ICI-Non-AIN AKI (n = 36) and ICI-treated patients without AKI (n = 16) (both P ≤ .0001); these findings were confirmed in the validation cohort from Spain (n = 19) with P-values of .0008 and <.0001, respectively. The area under the curve (AUC) for urinary CXCL-9 distinguishing ICI-AIN biopsy proven (combined from both cohorts, n = 45) from ICI-Non-AIN AKI was 0.83 (95% confidence interval 0.74-0.92), while for urinary TNF-α the AUC was 0.63 (0.51-0.75). CONCLUSIONS: Increased urinary CXCL-9 was superior to TNF-α as a biomarker for the non-invasive diagnosis of ICI-AIN, even after prior corticosteroid exposure, highlighting its promise as clinical diagnostic tool.
引用
- Chavez CCN, Bermejo S, Narvaez VC, et al. Urinary CXCL-9 outperforms TNF-α for non-invasive diagnosis of immune checkpoint inhibitor-associated acute interstitial nephritis. Nephrol Dial Transplant. 2026. PMID: 41642247. doi:10.1093/ndt/gfag016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。